Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease - Test2 - elhamkhani - TriplyDB

Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease

Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease

http://www.wikidata.org/entity/Q35498214

about

Discrepancies between patient-reported outcomes, and endoscopic and histological appearance in UC.Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis.

P2860

Q39167818-EE627F99-3FD6-4C36-909D-58BA0FB12C57 Q47692659-24F20D8C-18A9-4A1A-BBE0-BAF9D638E463

P2860

Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease

http://www.wikidata.org/entity/Q35498214

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Validation of gene expression ...... ical trials in Crohn's disease

@ast

Validation of gene expression ...... ical trials in Crohn's disease

@en

type

label

Validation of gene expression ...... ical trials in Crohn's disease

@ast

Validation of gene expression ...... ical trials in Crohn's disease

@en

prefLabel

Validation of gene expression ...... ical trials in Crohn's disease

@ast

Validation of gene expression ...... ical trials in Crohn's disease

@en

P1433

Q35498214-937D493E-226E-4C7D-93D9-D9D3CBC6CFB1

P1476

Q35498214-FE33D3E4-9639-4223-909C-2FA9B7D36CF0

P2093

Q35498214-0BAC6214-3F10-4B4A-999D-81F97338418E

Q35498214-106114B8-A206-443D-8158-D983FE682AA2

Q35498214-1BD69EEF-C4CE-4A69-A2B0-E8C29EE49A7C

Q35498214-203860BA-C532-4ACD-ACED-4804C7E55535

Q35498214-4054027A-9869-48AC-A26A-FF6E27D2EC20

Q35498214-62D21CCC-F41E-4B85-9921-DF8ED1C210A1

Q35498214-6E0FD7A3-3745-48E3-AD8E-BA17796B0EF3

Q35498214-8CAB4913-BF85-4995-BA7A-ABE313D13A08

Q35498214-9419CFBD-793C-4421-9B27-38E6B5E26AD3

Q35498214-A99B0FDD-615F-40B4-B294-BAAEB1453950

P2860

Q35498214-05AA9FB3-D5BD-4360-8CB9-DD587D339DC7

Q35498214-18C9401B-BD0F-41DA-AF9B-B250C4CEF2FE

Q35498214-217CDCE4-6C3A-4736-8196-739CA2592EE9

Q35498214-241452B4-26E7-4251-B395-BF17ED1D5213

Q35498214-3675457D-8CDD-4D46-8771-A1D907FB3D41

Q35498214-49F513B0-F20E-4691-B4BE-28F221EEDDBC

Q35498214-4E3E4EB6-962F-4971-8296-35BCC8DD23B6

Q35498214-504A905D-090B-4CF2-890B-0E04728C4B21

Q35498214-583D22F4-D460-40E5-9449-58E740B5B513

Q35498214-5C16D6EE-2FE3-46D9-810F-042C3B9DAE62

P304

Q35498214-16B069E3-1704-4AA3-8B71-D3DD3A660827

P31

Q35498214-DD546022-78E8-433F-886F-89901B4BD96E

P356

Q35498214-0681976A-2E46-447E-9742-73C19EFAE59F

P433

Q35498214-64E8DA39-625B-484F-B492-4F326526BE88

P478

Q35498214-BC5AEF95-35E9-41E1-8341-3BD9867CAA99

P50

Q35498214-2EAB5751-AC30-4988-B4F9-A4E320E55FA3

P577

Q35498214-1F251DB6-7302-4024-8805-0B548E32B783

P698

Q35498214-0C1FFB8D-4DCB-40A0-B106-701AA268EB6A

P921

Q35498214-5CAE7D79-139D-47FC-9BD1-1EC2C787B302

Q35498214-B604822F-94ED-45A6-BC82-F0E35CA6305D

P932

Q35498214-2A39C0C8-766A-457D-8252-4198B3D8FDBA

P356

MIB.0000000000000264

P1433

Inflammatory Bowel Diseases

P1476

Validation of gene expression ...... ical trials in Crohn's disease

@en

P2093

Barrett G Levesque

http://www.w3.org/2001/XMLSchema#string

Bing Zhang

http://www.w3.org/2001/XMLSchema#string

Brigid S Boland

http://www.w3.org/2001/XMLSchema#string

David L Boyle

http://www.w3.org/2001/XMLSchema#string

Gary S Firestein

http://www.w3.org/2001/XMLSchema#string

Guangyong Zou

http://www.w3.org/2001/XMLSchema#string

James Proudfoot

http://www.w3.org/2001/XMLSchema#string

Jesus Rivera-Nieves

http://www.w3.org/2001/XMLSchema#string

John T Chang

http://www.w3.org/2001/XMLSchema#string

Joshua Hillman

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Quantitative biomarker analysis of synovial gene expression by real-time PCR

Crohn's disease

Inflammatory bowel disease

Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.

Performance evaluation of coherence-based adaptive imaging using clinical breast data.

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.

Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels.

Validated gene expression biomarker analysis for biopsy-based clinical trials in ulcerative colitis.

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

P304

323-330

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000000264

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25545378

http://www.w3.org/2001/XMLSchema#string

P921

Crohn's disease

P932

4404151

http://www.w3.org/2001/XMLSchema#string